Penumbral Imaging-Based Thrombolysis with Tenecteplase Is Feasible up to 24 Hours after Symptom Onset
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose Thrombolysis >4.5 hours after ischemic stroke onset is unproven. We assessed the feasibility of tenecteplase (TNK) treatment in patients with evidence of an ischemic penumbra 4.5 to 24 hours after onset. Methods Acute ischemic stroke patients underwent perfusion computed tomography (CT)/ magnetic resonance imaging. Patients with cerebral blood volume (CBV) or diffusion weighted imaging Alberta Stroke Program Early CT Scores (ASPECTS) >6 and mismatch score >2 (defined as >2 ASPECTS regions with delay on mean transit time maps and normal CBV) were eligible for treatment with TNK (0.25 mg/kg). Patients with mismatch patterns enrolled in non-endovascular/ non-thrombolysis trials and those without mismatch patterns served as comparators. Results The median (interquartile range) baseline National Institutes of Health Stroke Scale (NIHSS) in TNK treated patients (n=16) was 12 (range, 8 to 15). In the untreated mismatch (n=18) and nonmismatch (n=23) groups, the baseline NIHSS was 12 (range, 7 to 12) and 16 (range, 8 to 20; P=0.09) respectively. There was one symptomatic hemorrhage each in the TNK group (parenchymal hematoma [PH] 2) and non-mismatch group (PH 2). Penumbral salvage volumes were higher in TNK treated patients (48.3 mL [range, 24.9 to 80.4]) than the non-mismatch (–90.8 mL [range, –197 to –20]; P<0.0001) patients. Conclusions This prospective, non-randomized study supports the feasibility of TNK therapy in patients with evidence of ischemic penumbra 4 to 24 hours after onset.
Abstract
Background and Purpose Thrombolysis >4.5 hours after ischemic stroke onset is unproven. We assessed the feasibility of tenecteplase (TNK) treatment in patients with evidence of an ischemic penumbra 4.5 to 24 hours after onset. Methods Acute ischemic stroke patients underwent perfusion computed tomography (CT)/ magnetic resonance imaging. Patients with cerebral blood volume (CBV) or diffusion weighted imaging Alberta Stroke Program Early CT Scores (ASPECTS) >6 and mismatch score >2 (defined as >2 ASPECTS regions with delay on mean transit time maps and normal CBV) were eligible for treatment with TNK (0.25 mg/kg). Patients with mismatch patterns enrolled in non-endovascular/ non-thrombolysis trials and those without mismatch patterns served as comparators. Results The median (interquartile range) baseline National Institutes of Health Stroke Scale (NIHSS) in TNK treated patients (n=16) was 12 (range, 8 to 15). In the untreated mismatch (n=18) and nonmismatch (n=23) groups, the baseline NIHSS was 12 (range, 7 to 12) and 16 (range, 8 to 20; P=0.09) respectively. There was one symptomatic hemorrhage each in the TNK group (parenchymal hematoma [PH] 2) and non-mismatch group (PH 2). Penumbral salvage volumes were higher in TNK treated patients (48.3 mL [range, 24.9 to 80.4]) than the non-mismatch (–90.8 mL [range, –197 to –20]; P<0.0001) patients. Conclusions This prospective, non-randomized study supports the feasibility of TNK therapy in patients with evidence of ischemic penumbra 4 to 24 hours after onset.
참고문헌 (30)
- Chen CH, "Stroke code improves intravenous thrombolysis administration in acute ischemic stroke", PLoS One, 9, pp.e104862~ (2014)[DOI]
- Gumbinger C, "Time to treatment with recombinant tissue plasminogen activator and outcome of stroke in clinical practice: retrospective analysis of hospital quality assurance data with comparison with results from randomised clinical trials", BMJ, 348, pp.g3429~ (2014)[DOI]
- Emberson J, "Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials", Lancet, 384, pp.1929~1935 (2014)[DOI]
- Parsons M, "A randomized trial of tenecteplase versus alteplase for acute ischemic stroke", N Engl J Med, 366, pp.1099~1107 (2012)[DOI]
- Davis SM, "Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial", Lancet Neurol, 7, pp.299~309 (2008)[DOI]
- Keyt BA, "A faster-acting and more potent form of tissue plasminogen activator", Proc Natl Acad Sci U S A, 91, pp.3670~3674 (1994)[DOI]
- Parsons MW, "Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window", Neurology, 72, pp.915~921 (2009)[DOI]
- Haley EC Jr, "A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke", Stroke, 36, pp.607~612 (2005)[DOI]
- Aviv RI, "Alberta Stroke Program Early CT scoring of CT perfusion in early stroke visualization and assessment", AJNR Am J Neuroradiol, 28, pp.1975~1980 (2007)[DOI]
- Butcher K, "Rapid assessment of perfusion-diffusion mismatch", Stroke, 39, pp.75~81 (2008)[DOI]
- Haley EC Jr, "Phase IIB", III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial, 2010, pp.41, 707~711
- Lindsay P, "Toward a more effective approach to stroke: Canadian Best Practice Recommendations for Stroke Care", CMAJ, 178, pp.1418~1425 (2008)[DOI]
- Abels B, "Perfusion CT in acute ischemic stroke: a qualitative and quantitative comparison of deconvolution and maximum slope approach", AJNR Am J Neuroradiol, 31, pp.1690~1698 (2010)[DOI]
- Bivard A, "Perfusion computed tomography to assist decision making for stroke thrombolysis", Brain, 138, pp.1919~1931 (2015)[DOI]
- Neumann-Haefelin T, "Effect of incomplete (spontaneous and postthrombolytic) recanalization after middle cerebral artery occlusion: a magnetic resonance imaging study", Stroke, 35, pp.109~114 (2004)[DOI]
- Neeb L, "Adapting the computed tomography criteria of hemorrhagic transformation to stroke magnetic resonance imaging", Cerebrovasc Dis Extra, 3, pp.103~110 (2013)[DOI]
- Smadja D, "A new therapeutic strategy for acute ischemic stroke: sequential combined intravenous tPA-tenecteplase for proximal middle cerebral artery occlusion based on first results in 13 consecutive patients", Stroke, 42, pp.1644~1647 (2011)[DOI]
- Huang X, "Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study", Lancet Neurol, 14, pp.368~376 (2015)[DOI]
- Coutts SB, "Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion", Stroke, 46, pp.769~774 (2015)[DOI]
- Buck D, "Reperfusion therapies for wake-up stroke: systematic review", Stroke, 45, pp.1869~1875 (2014)[DOI]
- Breuer L, "Feasibility and safety of magnetic resonance imaging-based thrombolysis in patients with stroke on awakening: initial single-centre experience", Int J Stroke, 5, pp.68~73 (2010)
- Aoki J, "Intravenous thrombolysis based on diffusion-weighted imaging and fluid-attenuated inversion recovery mismatch in acute stroke patients with unknown onset time", Cerebrovasc Dis, 31, pp.435~441 (2011)[DOI]
- Aoki J, "Negative fluid-attenuated inversion recovery-based intravenous thrombolysis using recombinant tissue plasminogen activator in acute stroke patients with unknown onset time", Cerebrovasc Dis Extra, 3, pp.35~45 (2013)[DOI]
- Ebinger M, "MRI-based intravenous thrombolysis in stroke patients with unknown time of symptom onset", Eur J Neurol, 19, pp.348~350 (2012)[DOI]
- Hill MD, "Tissue Window in Stroke Thrombolysis study (TWIST): a safety study", Can J Neurol Sci, 40, pp.17~20 (2013)[DOI]
- Manawadu D, "A case-controlled comparison of thrombolysis outcomes between wakeup and known time of onset ischemic stroke patients", Stroke, 44, pp.2226~2231 (2013)[DOI]
- Goyal M, "Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials", Lancet, 387, pp.1723~1131 (2016)[DOI]
- Campbell BC, "Endovascular therapy for ischemic stroke with perfusion-imaging selection", N Engl J Med, 372, pp.1009~1018 (2015)[DOI]
- Lin K, "Correlation of volumetric mismatch and mismatch of Alberta Stroke Program Early CT Scores on CT perfusion maps", Neuroradiology, 51, pp.17~23 (2009)[DOI]
- Goyal M, "Randomized assessment of rapid endovascular treatment of ischemic stroke", N Engl J Med, 372, pp.1019~1030 (2015)[DOI]